Multiple mechanisms have been tested in pain - How can we improve the chances of success?

Current Opinion in Pharmacology

Volumn 14, Issue 1, 2014, Pages 11-17

  Hayes, Ann G ^a   Arendt Nielsen, Lars ^b   Tate, Simon ^c  

^a St Johns Innovation Centre   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

^c Babraham Research Campus ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPSAICIN; CARBAMAZEPINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DULOXETINE; GABAPENTIN; KETAMINE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N METHYL DEXTRO ASPARTIC ACID; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA CONOTOXIN MVIIA; VANILLOID RECEPTOR 1; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ANALGESIC ACTIVITY; ARTICLE; CHRONIC PAIN; COMPLEX REGIONAL PAIN SYNDROME; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TREATMENT FAILURE; ENZYME INHIBITION; FIBROMYALGIA; HUMAN; MOLECULARLY TARGETED THERAPY; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; SENSITIZATION;

ANALGESICS; ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEURALGIA; PAIN; PAIN, INTRACTABLE;

EID: 84886828641     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.09.017     Document Type: Review

References (70)

1. J.S. Mogil Pain genetics: past, present and future Trends Genet 28 2012 258 266
2. H.G. Schaible, A. Ebersberger, and G. Natura Update on peripheral mechanisms of pain: beyond prostaglandins and cytokines Arthritis Res Ther 13 2011 210
3. C.A. von Hehn, R. Baron, and C.J. Woolf Deconstructing the neuropathic pain phenotype to reveal neural mechanisms Neuron 73 2012 638 652
4. T.H. Cheng Spinal cord mechanisms of chronic pain and clinical implications Curr Pain Headache Rep 14 2010 213 220
5. A.I. Basbaum, D.M. Bautista, G. Scherrer, and D. Julius Cellular and molecular mechanisms of pain Cell 139 2009 267 284
6. D. Schomberg, and J.K. Olson Immune responses of microglia in the spinal cord: contribution to pain states Exp Neurol 234 2012 262 270
7. C.M. Campbell, M.S. Kipnes, B.C. Stouch, K.L. Brady, M. Kelly, W.K. Schmidt, K.L. Petersen, M.C. Rowbotham, and J.N. Campbell Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy Pain 153 2012 1815 1823
8. S. Collins, M.J. Sigtermans, A. Dahan, W.W. Zuurmond, and R.S. Perez NMDA receptor antagonists for the treatment of neuropathic pain Pain Med 11 2010 1726 1742
9. M.P. Lunn, R.A. Hughes, and P.J. Wiffen Duloxetine for treating painful neuropathy or chronic pain Cochrane Database Syst Rev 7 2009 10.1002/14651858.CD007115.pub2 Art. No.: CD007115
10. S. Abou-Raya, A. Abou-Raya, and M. Helmii Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial Age Ageing 41 2012 646 652
11. A.S. Chappell, D. Desaiah, H. Liu-Seifert, S. Zhang, V. Skljarevski, Y. Belenkov, and J.P. Brown A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee Pain Pract: Official J World Inst Pain 11 2011 33 41
12. V. Morisset, J.B. Davis, and S.N. Tate Mechanism of action of anticonvulsant drugs as analgesic drugs S. McMahon, M. Koltzenburg, I. Tracey, D.C. Turk, Textbook of pain edn 6 2013 Elsevier Saunders 491 499
13. A. Moore, and H.J. McQuay Cyclooxygenase inhibitors: clinical use S. McMahon, M. Koltzenburg, I. Tracey, D.C. Turk, Textbook of pain edn 6 2013 Elsevier Saunders 455 464
14. G. Stefansdottir, M.L. De Bruin, M.J. Knol, D.E. Grobbee, and H.G.M. Leufkens Randomized Controlled Trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety Drug Saf 34 2011 783 792
15. E. Eisenberg, Y. Lurie, C. Braker, D. Daoud, and A. Ishay Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study Neurology 57 2001 505 509
16. R.L. Rauck, A. Shaibani, V. Biton, J. Simpson, and B. Koch Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study Clin J Pain 23 2007 150 158
17. A. Shaibani, S. Fares, J.L. Selam, A. Arslanian, J. Simpson, D. Sen, and Bongardt S: Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial J Pain 10 2009 818 828
18. A.I. Vinik, M. Tuchman, B. Safirstein, C. Corder, L. Kirby, K. Wilks, S. Quessy, D. Blum, J. Grainger, J. White, and M. Silver Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies Pain 128 2007 169 179
19. L. Hearn, S. Derry, and R.A. Moore Lacosamide for neuropathic pain and fibromyalgia in adults Cochrane Database Syst Rev 2 2012 CD009318 10.1002/14651858.CD009318.pub2
20. R. Baron, V. Mayoral, G. Leijon, A. Binder, I. Steigerwald, and M. Serpell Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analaysis from an open-label, two-stage adaptive, randomized, controlled trial Clin Drug Investig 29 2009 231 241
21. R. Raouf, K. Quick, and J.N. Wood Pain as a channelopathy J Clin Investig 120 2010 3745 3752
22. C.G. Faber, J.G. Hoeijmakers, H.S. Ahn, X. Cheng, C. Han, J.S. Choi, M. Estacion, G. Lauria, E.K. Vanhoutte, and M.M. Gerrits Gain of function Nav1.7 mutations in idiopathic small fiber neuropathy Ann Neurol 71 2012 26 39
23. F.G. Campbell, J.G. Graham, and K.J. Zilkha Clinical trial of carbamazepine (Tegretol) in trigeminal neuralgia J Neurol Neurosurg Psychiatry 29 1966 265 267
24. P.Y. Goldberg, N. Price, R. Namdari, C.J. Cohen, M.H. Lamers, C. Winters, J. Price, C.E. Young, H. Verschoof, and R. Sherrington Treatment of Nav1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker Pain 153 2012 80 85
25. J.M. Zakrzewska, and P.N. Patsalos Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia J Neurol Neurosurg Psychiatry 52 1989 472 476
26. G. Lunardi, M. Leandri, C. Albano, S. Cultrera, M. Fracassi, V. Rubino, and E. Favale Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia Neurology 48 1997 1714 1717
27. F. Rugiero, D. Derjean, V. Morisset, D. Owen, G.M. Giblin, J.B. Davis, K. Gunn, J. Palmer, and S.N. Tate CNV1014802, a novel, potent, nav1.7 selective, state-dependent sodium channel blocker with broad preclinical antihyperalgesic efficacy 3 Proceedings of the 14th World Congress of Pain, PT 172 Tuesday, August 28 2012
28. A.J. Thorpe, and J. Offord The alpha2-delta protein: an auxiliary subunit of voltage-dependent calcium channels as a recognised drug target Curr Opin Investig Drugs 11 2010 761 770
29. Z. Ali, J.E. Palmer, and V. Goli Anticonvulsants: clinical S. McMahon, M. Koltzenburg, I. Tracey, D.C. Turk, Textbook of pain 6th edition 2013 Elsevier Saunders 500 522
30. S. Quilici, J. Chancellor, M. Lothgren, D. Simon, G. Said, T.K. Le, A. Garcia-Cebrian, and B. Monz Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain BMC Neurol 9 2009 6 10.1186/1471-2377-9-6
31. J. Satoh, S. Yagihashi, M. Baba, M. Suzuki, A. Arakawa, T. Yoshiyama, and S. Shoji Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial Diabet Med 28 2011 109 116
32. R.A. Moore, S. Straube, P.J. Wiffen, S. Derry, and H.J. McQuay Pregabalin for acute and chronic pain in adults Cochrane Database Syst Rev 3 2009 CD007076 10.1002/14651858.CD76.0070.pub2
33. M.S. Wallace, S.G. Charapata, R. Fisher, M. Byas-Smith, P.S. Staats, M. Mayo, D. McGuire, and D. Ellis Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial Neuromodulation J Int Neuromodulation Soc 9 2006 75 86
34. J.G. McGivern Ziconotide: a review of its pharmacology and use in the treatment of pain Neuropsychiatr Dis Treat 3 2007 69 85
35. V. Morisset, D. Derjean, F. Rugiero, D. Owen, J.B. Davis, G.M. Giblin, C. Walls, J. Palmer, K. Gunn, and S.N. Tate CNV2197944 a novel potent and selective cav2.2 state-dependent blocker for evaluation in chronic pain Proceedings of the 14th World Congress of Pain, PT 155 Tuesday, August 28 2012
36. Y. Indo, M. Tsuruta, Y. Hayashida, M.A. Karim, K. Ohta, T. Kawano, H. Mitsubuchi, H. Tonoki, Y. Awaya, and I. Matsuda Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis Nat Genet 13 1996 485 488
37. A.J. Kivitz, J.S. Gimbel, C. Bramson, M.A. Nemeth, D.S. Keller, M.T. Brown, C.R. West, and K.M. Verburg Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain Pain 154 2013 1009 1021
38. M.T. Brown, F.T. Murphy, D.M. Radin, I. Davignon, M.D. Smith, and C.R. West Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial J Pain 13 2012 790 798
39. M.T. Brown, F.T. Murphy, D.M. Radin, I. Davignon, M.D. Smith, and R. West Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial Arthritis Rheum 65 2013 1795 1803
40. G. Romano, H. Wang, J. Ritz, M. Fedgchin, L. Russell, K. Kelly, and J. Thipphawong Analgesic efficacy of fulranumab in patients with neuropathic pain in a randomized, placebo-controlled, double-blind study Proceedings of the 14th World Congress of Pain, PT 452 Tuesday, August 28 2012
41. H. Wang, G. Romano, M.E. Frustaci, P. Sanga, S. Ness, L. Russell, M. Fedgchin, S. Vallow, K. Kelly, and J. Thipphawong Analgesic efficacy of fulranumab in patients with painful diabetic peripheral neuropathy in a randomized, placebo-controlled,double-blind study Proceedings of the 14th World Congress of Pain, PT 453 Tuesday, August 28 2012
42. P. Anand, R. Shenoy, J.E. Palmer, A.J. Baines, R.Y. Lai, J. Robertson, N. Bird, T. Ostenfeld, and B.A. Chizh Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury Eur J Pain 15 2011 1040 1048
43. J. Daves, R. Aitchison, S.G. Miller, and K. Witt A randomized, placebo-controlled phase 2 study of ARRY-797 in patients with osteoarthritis pain refractory to NSAID treatment showed statistically significant improvements in WOMAC pain and in biomarkers of bone and cartilage degradation American College of Rheumatology Annual Meeting November 13 2012
44. P. Huggins, T. Smart, S. Langman, L. Taylor, and T. Young An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee Pain 153 2012 1837 1846
45. J. Kalliomaki, N. Attal, B. Jonzon, F.W. Back, K. Huizar, S. Ratcliffe, B. Eriksson, M. Janecki, A. Danilov, and D. Bouhassira A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia Pain 154 2013 761 767
46. G. Svensson, C. Thorne, F. Miller, M. Bjornsson, A. Reimfelt, and R.A. Karlsten Phase II randomised controlled trial evaluating the efficacy and safety of the TRPV-1 antagonist AZD1386 in osteoarthritis of the knee Proceedings of the 13th World Congress of Pain, PM 379 Monday, August 30 2010
47. H. Quiding, B. Jonzon, O. Svensson, L. Webster, A. Reimfelt, A. Karin, R. Karlsten, and M. Segerdahl TRPV1 antagonistic analgesic effect: a randomized study of AZD1386 in pain after third molar extraction Pain 154 2013 808 812
48. E.C. Keystone, M.M. Wang, M. Layton, S. Hollis, and I.B. McInnes Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine Ann Rheum Dis 71 2012 1630 1635
49. T.C. Stock, B.J. Bloom, N. Wei, S. Ishaq, W. Park, X. Wang, P. Gupta, and C.A. Mebus Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate J Rheumatol 39 2012 720 727
50. R.P. Landry, V.L. Jacobs, E.A. Romero-Sandoval, and J.A. DeLeo Propentofylline, a CNS glial modulator does not decrease pain in post-herpetic neuralgia patients: in vitro evidence for differential responses in human and rodent microglia and macrophages Exp Neurol 234 2012 340 350
51. M.C. Rowbotham, W.R. Duan, J. Thomas, W. Nothaft, and M.M. Backonja A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain Pain 146 2009 245 252
52. M.C. Rowbotham, A. Arslanian, W. Nothaft, W.R. Duan, A.E. Best, Y. Pritchett, Q. Zhou, and B.R. Stacey Efficacy and safety of the α4β2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain Pain 153 2012 862 868
53. M.S. Wallace, M.C. Rowbotham, N.P. Katz, R.H. Dworkin, R.M. Dotson, B.S. Galer, R.L. Rauck, M.M. Backonja, S.N. Quessy, and P.D. Meisner A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain Neurology 59 2002 1694 1700
54. J.R. Sneyd, J.A. Langton, L.G. Allan, J.E. Peacock, and D.J. Rowbotham Multicentre evaluation of the adenosine agonist GR79236X in patients with dental pain after third molar extraction Br J Anaesth 98 2007 672 676
55. T. Ostenfeld, J. Price, M. Albanese, J. Bullman, F. Guillard, I. Meyer, R. Leeson, C. Costantin, L. Ziviani, F.P. Nocini, and S. Miller A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar extraction Clin J Pain 27 2011 668 676
56. S. Boyce, and R.G. Hill Substance P (NK1) receptor antagonists - analgesics or not? Tachykinins Handb Exp Pharmacol 164 2004 441 457
57. O.G. Berge Predictive validity of behavioural animal models for chronic pain Br J Pharmacol 164 2011 1195 1206
58. J.S. Mogil, K.D. Davis, and S.W. Derbyshire The necessity of animal models in pain research Pain 151 2010 12 17
59. L. Arendt-Nielsen, M. Curatolo, and A. Drewes Human experimental pain models in drug development: translational pain research Curr Opin Invest Drug 8 2007 41 53
60. L. Arendt-Nielsen, and H.C. Hoeck Optimizing the early phase development of new analgesics by human pain biomarkers Expert Rev Neurother 11 2011 1631 1651
61. L. Arendt-Nielsen, and D. Yarnitsky Experimental and clinical applications of quantitative sensory testing applied to skin, muscles and viscera J Pain 10 2009 556 572
62. B.A. Chizh, and C.N. Sang Use of sensory methods for detecting target engagement in clinical trials of new analgesics Neurotherapeutics 6 2009 749 754
63. P. Morgan, P.H. Van Der Graaf, J. Arrowsmith, D.E. Feltner, K.S. Drummond, C.D. Wegner, and S.D. Street Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival Drug Discov Today 17 2012 419 424
64. C. Stahl, L.L. Christrup, S.D. Andersen, L. Arendt-Nielsen, and A.M. Drewes A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model Pain 123 2006 28 36
65. L. Arendt-Nielsen, A.E. Olesen, C. Ståhl, F. Menzaghi, S. Kell, G.Y. Wong, and A.M. Drewes Analgesic efficacy of peripheral Kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model Anesthesiology 111 2009 616 624
66. P. Gazerani, C. Staahl, A.M. Drewes, and L. Arendt-Nielsen The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization Pain 122 2006 315 325
67. D.A. Simpson Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy J Clin Neuromuscular Dis 3 2001 53 62
68. S.A. Schug Opioids: clinical use S. McMahon, M. Koltzenburg, I. Tracey, D.C. Turk, Textbook of pain 6th edition 2013 Elsevier Saunders 429 443
69. P.J. Wiffen, S. Derry, R.A. Moore, and H.J. McQuay Carbamazepine for acute and chronic pain in adults Cochrane Database Syst Rev 1 2011 CD005451 10.1002/14651858.CD51.0054.pub2
70. S. Derry, A. Sven-Rice, P. Cole, T. Tan, and R.A. Moore Topical capsaicin (high concentration) for chronic neuropathic pain in adults Cochrane Database Syst Rev 2 2013 10.1002/14651858.CD007393.pub3 CD007393